{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:55:12Z","timestamp":1774860912303,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hbpd.2025.12.016","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:22:47Z","timestamp":1766506967000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world impact of the management of advanced perihilar and extrahepatic cholangiocarcinoma on prognosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Marie","family":"Decraecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Aurillac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2025.12.016_bib0001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol. Hepatol."},{"key":"10.1016\/j.hbpd.2025.12.016_bib0002","article-title":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: a nationwide retrospective analysis","volume":"15","author":"Neuzillet","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0003","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0004","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0006","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0007","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhep.2010.06.039","article-title":"Trends in the incidence and management of biliary tract cancer: a French population-based study","volume":"54","author":"Lepage","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0008","unstructured":"SPF. Survival of people with cancer in metropolitan France 1989-2018 - vesicle and bile ducts. Available from: https:\/\/www.santepubliquefrance.fr\/import\/survie-des-personnes-atteintes-de-cancer-en-france-metropolitaine-1989-2018-vesicule-et-voies-biliaires."},{"key":"10.1016\/j.hbpd.2025.12.016_bib0009","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0011","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0013","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/cam4.5282","article-title":"Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment","volume":"12","author":"Cosgrove","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390887","article-title":"Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma","volume":"15","author":"Madzikatire","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0015","article-title":"Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer","volume":"4","author":"Thol","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42083-4","article-title":"Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment","volume":"13","author":"Doleschal","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0019","article-title":"Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2)","volume":"5","author":"Bridgewater","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0020","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1080\/14796694.2024.2379237","article-title":"Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA","volume":"20","author":"Wang","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0021","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1111\/liv.15948","article-title":"Management of intrahepatic and perihilar cholangiocarcinomas: guidelines of the French association for the study of the liver (AFEF)","volume":"44","author":"Neuzillet","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","article-title":"The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature","volume":"42","author":"Pillay","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hbpd.2025.12.016_bib0023","doi-asserted-by":"crossref","first-page":"c951","DOI":"10.1136\/bmj.c951","article-title":"Multidisciplinary team working in cancer: what is the evidence?","volume":"340","author":"Taylor","year":"2010","journal-title":"BMJ"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387225002309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387225002309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:06:02Z","timestamp":1774857962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387225002309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1499387225002309"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.016","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of the management of advanced perihilar and extrahepatic cholangiocarcinoma on prognosis","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}